

Anaplastic lymphoma kinase Non Small Cell Lung Cancer (ALK-NSCLC) - Epidemiology Forecast to 2030

<https://marketpublishers.com/r/A1BA2C627F19EN.html>

Date: May 2020

Pages: 100

Price: US\$ 2,850.00 (Single User License)

ID: A1BA2C627F19EN

Abstracts

This report can be delivered to the clients within 24 Hours

DelveInsight's 'Anaplastic lymphoma kinase-Non Small Cell Lung Cancer (ALK-NSCLC)- Epidemiology Forecast to 2030' report delivers an in-depth understanding of the disease, historical and forecasted ALK NSCLC epidemiology in the 7MM, i.e., the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan.

Anaplastic lymphoma kinase Non-Small Cell Lung Cancer (ALK-NSCLC) Understanding

Lung cancer mainly begins in the lungs, and it may spread to lymph nodes or other organs in the body, such as the brain. However, cancer from other organs may also spread to the lungs. When cancer cells spread from one organ to another, they are called metastases.

There are mainly two types of lung cancer small cell lung cancer (SCLC) and non-small cell lung cancer (NSCLC). NSCLC can be defined as any type of epithelial lung cancer other than SCLC. It is mainly subcategorized into adenocarcinomas, squamous cell carcinomas, large cell carcinomas and several other types that occur less frequently include adenosquamous carcinomas, and sarcomatoid carcinomas. In these subtypes adenocarcinoma accounts for highest number of cases, i.e., approximately 47% followed by Squamous Cell Carcinoma and Large Cell Carcinoma..

There are several genetic mutations identified to play a major role in the progression of this indication. Mutations in EGFR, KRAS, and ALK are mutually exclusive in patients with NSCLC, and the presence of one mutation instead of another can influence

response to targeted therapy. There are several mutations associated with NSCLC but the most common are EGFR, KRAS, ROS-1, BRAF, C-Met, PD-L1 expression and others. Among all the mutations ALK mutation accounted for approximately 4% of the total cases of NSCLC.

ALK-positive mutation was discovered in 2007. ALK-positive lung cancers harbor a gene rearrangement referred to as the EML4-ALK fusion gene, compose a subset of tumors for which medical treatment has expanded rapidly (along with survival) in the past few years. An ALK mutation is diagnosed by molecular profiling of a sample of the tumor. It's important in doing this testing that an adequate supply of tissue from either a lung biopsy or lung cancer surgery is obtained. Researchers are also looking at ways to determine if an ALK mutation is present before genetic testing is done, or could substitute for genetic testing.

Epidemiology Perspective by DelveInsight

The ALK NSCLC epidemiology division provides the insights about historical and current patient pool and forecasted trend for each seven major countries. The ALK NSCLC epidemiology data are studied through ALK NSCLC possible division to give a better understanding of the Disease scenario in the 7MM.

The disease epidemiology covered in the report provides historical as well as forecasted Anaplastic lymphoma kinase-Non Small Cell Lung Cancer epidemiology [segmented as Total Incidence of NSCLC Total Incident cases of NSCLC patients by Histology, Total Diagnosed cases of NSCLC patients by Stages, Total ALK-NSCLC cases, and Treated Patient Pool of ALK-NSCLC] scenario of Anaplastic lymphoma kinase-Non Small Cell Lung Cancer in the 7MM covering the United States, EU5 countries (Germany, France, Italy , Spain, and the United Kingdom), and Japan from 2017 to 2030.

Anaplastic lymphoma kinase Non-Small Cell Lung Cancer Detailed Epidemiology Segmentation

Total incident population of NSCLC in the 7MM was assessed to be 4,84,726 in 2017.

Total incident population of ALK NSCLC in the 7MM was assessed to be 22,197 in 2017.

The total incident cases of ALK NSCLC in the United States were found to be

8,449 in 2017 which is expected grow during the study period, i.e., 2017–2030.

In case of EU-5, Germany hold upto around 29% of the EU-5 Patient population. Japan accounts upto 5,000 ALK-Positive cases in 2017.

Scope of the Report

The ALK NSCLC report covers a detailed overview explaining its causes, symptoms, classification, pathophysiology, diagnosis and treatment patterns.

The ALK NSCLC Report and Model provide an overview of the risk factors and global trends of ALK NSCLC in the seven major markets (7MM: United States, Germany, France, Italy, Spain, and the United Kingdom, and Japan).

The report provides insight about the historical and forecasted patient pool of ALK NSCLC in seven major markets covering the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan.

The report helps to recognize the growth opportunities in the 7MM with respect to the patient population.

The report assesses the disease risk and burden and highlights the unmet needs of ALK NSCLC.

The report provides the segmentation of the ALK NSCLC epidemiology by total Incidence of NSCLC in the 7MM.

The report provides the segmentation of the ALK NSCLC epidemiology by total diagnosed cases of NSCLC patients by Stages in the 7MM.

The report provides the segmentation of the ALK NSCLC epidemiology by Histology in the 7MM.

The report provides the segmentation of the ALK NSCLC epidemiology by Treated Patient Pool of ALK NSCLC in the 7MM.

Report Highlights

11-Year Forecast of Anaplastic lymphoma kinase Non-Small Cell Lung Cancer epidemiology

7MM Coverage

Total Incident Cases of Non-Small Cell Lung Cancer

Incident Cases according to segmentation: Histology, ALK-NSCLC

Treated cases of Anaplastic lymphoma kinase Non-Small Cell Lung Cancer

KOL-Views

We interview, KOL's and SME's opinion through primary research to fill the data gaps and validate our secondary research. The opinion helps to understand the total patient population and current treatment pattern. This will support the clients in potential upcoming novel treatment by identifying the over ALK NSCLC scenario of the indications.

Key Questions Answered

What will be the growth opportunities in the 7MM with respect to the patient population pertaining to Anaplastic lymphoma kinase-Non Small Cell Lung Cancer ?

What are the key findings pertaining to the Anaplastic lymphoma kinase-Non-Small Cell Lung Cancer epidemiology across the 7MM and which country will have the highest number of patients during the study period (2017–2030)?

What would be the total number of patients of Anaplastic lymphoma kinase-Non-Small Cell Lung Cancer across the 7MM during the study period (2017–2030)?

Among the EU5 countries, which country will have the highest number of patients during the study period (2017–2030)?

At what CAGR the patient population is expected to grow in the 7MM during the study period (2017–2030)?

What are the various recent and upcoming events which are expected to improve the diagnosis of Anaplastic lymphoma kinase-Non-Small Cell Lung Cancer?

Reasons to buy

The Anaplastic lymphoma kinase-Non Small Cell Lung Cancer Epidemiology report will allow the user to -

- Develop business strategies by understanding the trends shaping and driving the global Anaplastic lymphoma kinase-Non Small Cell Lung Cancer market

- Quantify patient populations in the global Anaplastic lymphoma kinase-Non Small Cell Lung Cancer market to improve product design, pricing, and launch plans

- Organize sales and marketing efforts by identifying the age groups and sex that present the best opportunities for Anaplastic lymphoma kinase-Non Small Cell Lung Cancer therapeutics in each of the markets covered

- Understand the magnitude of Anaplastic lymphoma kinase-Non Small Cell Lung Cancer population by its severity

The Anaplastic lymphoma kinase-Non Small Cell Lung Cancer epidemiology report and model were written and developed by Masters and PhD level epidemiologists

The Anaplastic lymphoma kinase-Non Small Cell Lung Cancer Epidemiology Model developed by DelveInsight is easy to navigate, interactive with dashboards, and epidemiology based with transparent and consistent methodologies. Moreover, the model supports data presented in the report and showcases disease trends over 11-year forecast period using reputable sources

Key Assessments

Patient Segmentation

Disease Risk and Burden

Risk of disease by the segmentation

Factors driving growth in a specific patient population

Geographies Covered

The United States

EU5 (Germany, France, Italy, Spain, and the United Kingdom)

Japan

Study Period: 2017–2030

Total Incident cases of ALK NSCLC in the United States was assessed to be 8,449 in 2017, and are expected to increase during the study period. Among the European 5 countries, Germany had Incident population of ALK NSCLC. On the other hand, Spain had the lowest incident cases of ALK NSCLC in 2017.

Contents

1. KEY INSIGHTS

2. EXECUTIVE SUMMARY OF ALK-NSCLC

3. SWOT ANALYSIS OF ALK-NSCLC

4. ALK-NSCLC: MARKET OVERVIEW AT A GLANCE

4.1. Total Incidence Share (%) Distribution of NSCLC in 2017: By Country

4.2. Total Incidence Share (%) Distribution of NSCLC in 2030: By Country

5. ALK-NON-SMALL CELL LUNG CANCER (NSCLC): DISEASE BACKGROUND AND OVERVIEW

5.1. Introduction

5.1.1. Cellular Classification of NSCLC

5.1.2. Signs and Symptoms of NSCLC

5.1.3. Risk Factors of Lung Cancer

5.1.4. Causes of NSCLC

5.1.5. Disease Biology: NSCLC

6. DIAGNOSIS OF NSCLC

6.1. Diagnostic Algorithm for NSCLC

6.2. Stages of NSCLC

6.3. Staging System

7. EPIDEMIOLOGY AND PATIENT POPULATION

7.1. Epidemiology Key Findings

7.2. Assumptions and Rationale: 7MM

7.3. Epidemiology Scenario: 7MM

7.3.1. Total Incident cases of NSCLC patients in the 7MM

7.3.2. Total Incident cases of NSCLC patients by Histology in the 7MM

7.3.3. Total Diagnosed cases of NSCLC patients by Stages in the 7MM

7.4. The United States Epidemiology

7.4.1. Total Incident cases of NSCLC patients in the United States

- 7.4.2. Total Incident cases of NSCLC patients by Histology in the United States
- 7.4.3. Total Diagnosed cases of NSCLC patients by Stages in the United States
- 7.4.4. Total ALK NSCLC cases in the United States
- 7.4.5. Total ALK NSCLC Treated patient Pool in the United States

8. EU-5 EPIDEMIOLOGY

8.1. Germany

- 8.1.1. Total Incident cases of NSCLC patients in Germany
- 8.1.2. Total Incident cases of NSCLC patients by Histology in Germany
- 8.1.3. Total Diagnosed cases of NSCLC patients by Stages in Germany
- 8.1.4. Total ALK NSCLC cases in Germany
- 8.1.5. Total ALK NSCLC Treated patient Pool in Germany

8.2. France

- 8.2.1. Total Incident cases of NSCLC patients in France
- 8.2.2. Total Incident cases of NSCLC patients by Histology in France
- 8.2.3. Total Diagnosed cases of NSCLC patients by Stages in France
- 8.2.4. Total ALK NSCLC cases in France
- 8.2.5. Total ALK NSCLC Treated patient Pool in France

8.3. Italy

- 8.3.1. Total Incident cases of NSCLC patients in Italy
- 8.3.2. Total Incident cases of NSCLC patients by Histology in Italy
- 8.3.3. Total Diagnosed cases of NSCLC patients by Stages in Italy
- 8.3.4. Total ALK NSCLC cases in Italy
- 8.3.5. Total ALK NSCLC Treated patient Pool in Italy

8.4. Spain

- 8.4.1. Total Incident cases of NSCLC patients in Spain
- 8.4.2. Total Incident cases of NSCLC patients by Histology in Spain
- 8.4.3. Total Diagnosed cases of NSCLC patients by Stages in Spain
- 8.4.4. Total ALK NSCLC cases in Spain
- 8.4.5. Total ALK NSCLC Treated patient Pool in Spain

8.5. The United Kingdom

- 8.5.1. Total Incident cases of NSCLC patients in the United Kingdom
- 8.5.2. Total Incident cases of NSCLC patients by Histology in the United Kingdom
- 8.5.3. Total Diagnosed cases of NSCLC patients by Stages in the United Kingdom
- 8.5.4. Total ALK NSCLC cases in the United Kingdom
- 8.5.5. Total ALK NSCLC Treated patient Pool in the United Kingdom

9. JAPAN EPIDEMIOLOGY

9.1. Japan

9.1.1. Total Incident cases of NSCLC patients in Japan

9.1.2. Total Incident cases of NSCLC patients by Histology in Japan

9.1.3. Total Diagnosed cases of NSCLC patients by Stages in Japan

9.1.4. Total ALK NSCLC cases in Japan

9.1.5. Total ALK NSCLC Treated patient Pool in Japan

10. APPENDIX

10.1. Bibliography

10.2. Report Methodology

11. DELVEINSIGHT CAPABILITIES

12. DISCLAIMER

13. ABOUT DELVEINSIGHT

List Of Tables

LIST OF TABLES

Table 1 Summary of Non-small-cell Lung Cancer (NSCLC) Market, Epidemiology, and Key Events (2017–2030)

Table 2 TNM Staging of NSCLC

Table 3 Total Incident cases of NSCLC patients in the 7MM (2017–2030)

Table 4 Total Incident cases of NSCLC patients by Histology in the 7MM (2017–2030)

Table 5 Total Diagnosed cases of NSCLC patients by Stages in the 7MM (2017–2030)

Table 6 Total Incident cases of NSCLC patients in the United States (2017–2030)

Table 7 Total Incident cases of NSCLC patients by Histology in the United States (2017–2030)

Table 8 Total Diagnosed cases of NSCLC patients by Stages in the United States (2017–2030)

Table 9 Total ALK NSCLC cases in the United States

Table 10 Total ALK NSCLC Treated patient Pool in the United States

Table 11 Total Incident cases of NSCLC patients in Germany (2017–2030)

Table 12 Total Incident cases of NSCLC patients by Histology in Germany (2017–2030)

Table 13 Total Diagnosed cases of NSCLC patients by Stages in Germany (2017–2030)

Table 14 Total ALK NSCLC cases in Germany

Table 15 Total ALK NSCLC Treated patient Pool in Germany

Table 16 Total Incident cases of NSCLC patients in France (2017–2030)

Table 17 Total Incident cases of NSCLC patients by Histology in France (2017–2030)

Table 18 Total Diagnosed cases of NSCLC patients by Stages in France (2017–2030)

Table 19 Total ALK NSCLC cases in France

Table 20 Total ALK NSCLC Treated patient Pool in France

Table 21 Total Incident cases of NSCLC patients in Italy (2017–2030)

Table 22 Total Incident cases of NSCLC patients by Histology in Italy (2017–2030)

Table 23 Total Diagnosed cases of NSCLC patients by Stages in Italy (2017–2030)

Table 24 Total ALK NSCLC cases in Italy

Table 25 Total ALK NSCLC Treated patient Pool in Italy

Table 26 Total Incident cases of NSCLC patients in Spain (2017–2030)

Table 27 Total Incident cases of NSCLC patients by Histology in Spain (2017–2030)

Table 28 Total Diagnosed cases of NSCLC patients by Stages in Spain (2017–2030)

Table 29 Total ALK NSCLC cases in Spain

Table 30 Total ALK NSCLC Treated patient Pool in Spain

Table 31 Total Incident cases of NSCLC patients in the United Kingdom (2017–2030)

Table 32 Total Incident cases of NSCLC patients by Histology in the United Kingdom

(2017–2030)

Table 33 Total Diagnosed cases of NSCLC patients by Stages in the United Kingdom (2017–2030)

Table 34 Total ALK NSCLC cases in the United Kingdom

Table 35 Total ALK NSCLC Treated patient Pool in the United Kingdom

Table 36 Total Incident cases of NSCLC patients in Japan (2017–2030)

Table 37 Total Incident cases of NSCLC patients by Histology in Japan (2017–2030)

Table 38 Total Diagnosed cases of NSCLC patients by Stages in Japan (2017–2030)

Table 39 Total ALK NSCLC cases in Japan

Table 40 Total ALK NSCLC Treated patient Pool in Japan

List Of Figures

LIST OF FIGURES

Figure 1 ALK NSCLC SWOT Analysis

Figure 2 Major Types of NSCLC

Figure 3 Sign and Symptoms of NSCLC

Figure 4 Risks Factors of NSCLC

Figure 5 Alterations in Targetable Oncogenic Pathways in LUAD and LUSC

Figure 6 Schematic Illustration of the NSCLC Staging

Figure 7 Stage IA Lung Cancer

Figure 8 Stage IB Lung Cancer

Figure 9 Stage IIA Lung Cancer

Figure 10 Stage IIB Lung Cancer

Figure 11 Stage IIIA Lung Cancer

Figure 12 Stage IIIB Lung Cancer

Figure 13 Stage IVA Lung Cancer

Figure 14 Global Heat Map of Lung Cancer

Figure 15 Total Incident cases of NSCLC patients in the 7MM (2017–2030)

Figure 16 Total Incident cases of NSCLC patients by Histology in the 7MM (2017–2030)

Figure 17 Total Diagnosed cases of NSCLC patients by Stages in the 7MM
(2017–2030)

Figure 18 Total Incident cases of NSCLC patients in the United States (2017–2030)

Figure 19 Total Incident cases of NSCLC patients by Histology in the United States
(2017–2030)

Figure 20 Total Diagnosed cases of NSCLC patients by Stages in the United States
(2017–2030)

Figure 21 Total ALK NSCLC cases in the United States

Figure 22 Total ALK NSCLC Treated patient Pool in the United States

Figure 23 Total Incident cases of NSCLC patients in Germany (2017–2030)

Figure 24 Total Incident cases of NSCLC patients by Histology in Germany
(2017–2030)

Figure 25 Total Diagnosed cases of NSCLC patients by Stages in Germany
(2017–2030)

Figure 26 Total ALK NSCLC cases in Germany

Figure 27 Total ALK NSCLC Treated patient Pool in Germany

Figure 28 Total Incident cases of NSCLC patients in France (2017–2030)

Figure 29 Total Incident cases of NSCLC patients by Histology in France (2017–2030)

Figure 30 Total Diagnosed cases of NSCLC patients by Stages in France (2017–2030)

Figure 31 Total ALK NSCLC cases in France

Figure 32 Total ALK NSCLC Treated patient Pool in France

Figure 33 Total Incident cases of NSCLC patients in Italy (2017–2030)

Figure 34 Total Incident cases of NSCLC patients by Histology in Italy (2017–2030)

Figure 35 Total Diagnosed cases of NSCLC patients by Stages in Italy (2017–2030)

Figure 36 Total ALK NSCLC cases in Italy

Figure 37 Total ALK NSCLC Treated patient Pool in Italy

Figure 38 Total Incident cases of NSCLC patients in Spain (2017–2030)

Figure 39 Total Incident cases of NSCLC patients by Histology in Spain (2017–2030)

Figure 40 Total Diagnosed cases of NSCLC patients by Stages in Spain (2017–2030)

Figure 41 Total ALK NSCLC cases in Spain

Figure 42 Total ALK NSCLC Treated patient Pool in Spain

Figure 43 Total Incident cases of NSCLC patients in the United Kingdom (2017–2030)

Figure 44 Total Incident cases of NSCLC patients by Histology in the United Kingdom (2017–2030)

Figure 45 Total Diagnosed cases of NSCLC patients by Stages in the United Kingdom (2017–2030)

Figure 46 Total ALK NSCLC cases in the United Kingdom

Figure 47 Total ALK NSCLC Treated patient Pool in the United Kingdom

Figure 48 Total Incident cases of NSCLC patients in Japan (2017–2030)

Figure 49 Total Incident cases of NSCLC patients by Histology in Japan (2017–2030)

Figure 50 Total Diagnosed cases of NSCLC patients by Stages in Japan (2017–2030)

Figure 51 Total ALK NSCLC cases in Japan

Figure 52 Total ALK NSCLC Treated patient Pool in Japan

I would like to order

Product name: Anaplastic lymphoma kinase Non Small Cell Lung Cancer (ALK-NSCLC) - Epidemiology Forecast to 2030

Product link: <https://marketpublishers.com/r/A1BA2C627F19EN.html>

Price: US\$ 2,850.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/A1BA2C627F19EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970

